Similarly, in RAS-mutant cancers, inhibition of MEK or ERK alone is not sufficient to suppress tumor growth but combined inhibition of the two kinases results in a deeper and more durable pathway suppression and tumor growth control in multiple xenograft models [33]. The gene discussed is MAP2K7; the disease is cancer.